NRC and KalGene Develop New Alzheimer's Treatment
Patients are one step closer to receiving novel treatment for disease
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 06/05/15 -- Canadian biotech KalGene Pharmaceuticals has successfully secured $1.5 million in financing from Brain Canada, CQDM, and the Ontario Brain Institute (OBI) Focus on Brain program to develop a new treatment for Alzheimer's. This funding from CQDM will allow KalGene to test the conjugated therapeutic in preclinical models and if successful, in patients.
Getting therapeutics past the blood-brain barrier is no easy task. To enable its delivery into the brain, experts from the National Research Council of Canada (NRC) will couple KAL-ABP, the therapeutic molecule, to carrier molecules that can shuttle it past the barrier. The molecule, called Amyloid-binding peptide (KAL-ABP), was developed by NRC and licensed to KalGene earlier this year.
To assist with the evaluation of the therapy, the Montreal Neurological Institute is providing best-in-class human imaging, while the Centre for Imaging Technology Commercialization (CIMTEC) is developing an algorithm to automatically quantify amyloid-beta, the suspected cause of Alzheimer's disease.
Quick Facts
Quotes
"It is very rewarding to see NRC discoveries moving beyond our laboratories and toward patients, where they have the potential to make a difference for Canadians. We are happy to co-develop this new therapy with KalGene and ensure its smooth transition to clinical trials."
Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada
"We are extremely pleased with the world-class collaborative team that has been brought together to accelerate our Alzheimer's program."
Nathan T. Yoganathan, President and Chief Scientific Officer of KalGene Pharmaceuticals
"KalGene's approach to mitigating the progression of Alzheimer's disease pathophysiology represents an exciting technological advance, which brings hope to patients, families and individuals at high risk. It is expected that our innovations in Alzheimer's disease research will rapidly deliver tangible benefits for clinical populations."
Dr. Louis Collins, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University
"CIMTEC is proud to be playing a role in this important project, working alongside an elite team of experts to potentially bring the first effective Alzheimer's therapy to the world."
Bart Sullivan, Chief Executive Officer, CIMTEC
Additional Links:
-
-
-
Contacts:
Media Relations Team
National Research Council of Canada
1-855-282-1637 (toll-free, 24/7, in Canada only)
1-613-991-1431 (elsewhere in North America)
Twitter: (at)nrc_cnrc
T. Nathan Yoganathan
President and Chief scientific officer
KalGene Pharmaceuticals
1-613-770-2638
Anita Kar, Communications Officer
Montreal Neurological Institute, McGill University
T: 514 398-3376
M: 514 295-3870
Twitter: (at)TheNeuro_MNI
Darlene Pratt
Director of Marketing Communications
CIMTEC
1-519-858-5013 ext. 25324
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.06.2015 - 10:17 Uhr
Sprache: Deutsch
News-ID 398475
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Government & Administration
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NRC and KalGene Develop New Alzheimer's Treatment"
steht unter der journalistisch-redaktionellen Verantwortung von
National Research Council Canada-NRC and McGill University and KalGene Pharmaceuticals, Inc. and CIM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
